查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2004595

阿茲海默症診斷和治療市場：2026年至2030年全球市場預測（按產品、藥物類別、患者群體、疾病階段、最終用戶和分銷管道分類）

Alzheimer's Disease Diagnostics & Therapeutics Market by Product, Drug Class, Patient Demographics, Disease Stage, End User, Distribution Channel - Global Forecast 2026-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2024 年阿茲海默症診斷和治療市場價值為 83.5 億美元，預計到 2025 年將成長至 91.2 億美元，複合年成長率為 9.50%，到 2030 年將達到 144.1 億美元。

主要市場統計數據
基準年 2024 83.5億美元
預計年份：2025年 91.2億美元
預測年份 2030 144.1億美元
複合年成長率 (%) 9.50%

這份文件揭示了影響阿茲海默症診斷和治療未來發展的關鍵背景、科學挑戰和行業促進因素。

全球對抗阿茲海默症的鬥爭已迎來轉折點。分子生物學、神經影像學和生物標記發現領域的進步正在重新定義疾病的診斷和治療方式。曾經被視為不可避免的衰退，如今已成為嚴謹科學研究的對象，新的診斷方法和治療策略正在不斷出現。隨著患者、看護者、臨床醫生和政策制定者對早期發現和更精準干預的迫切需求日益成長，學術界、產業界和監管機構的相關人員正積極行動起來，以滿足這一迫切需要。

在快速發展的醫療保健生態系統中，找出能夠重新定義阿茲海默症研究、診斷創新和治療策略的變革性變化。

阿茲海默症領域正經歷著翻天覆地的變革，這主要得益於生物標記檢驗、新一代影像技術以及數位醫療融合方面的突破性進展。最初，該領域僅依賴症狀評估，但如今已轉向整合分子診斷技術，以便在臨床症狀出現之前很久就檢測到致病過程。這種轉變正在加速標靶單株抗體、緩解疾病小分子藥物以及旨在干預無症狀或前驅期階段的聯合治療的研發。

評估 2025 年美國關稅對阿茲海默症。

美國將於2025年對診斷設備、藥品生產原料和研究試劑加徵新關稅，這對阿茲海默症領域的各個層面都產生了影響。這些政策調整正在影響生物標記、造影劑和單株抗體組件的籌資策略。先前依賴低成本進口的機構現在正在評估國內產能，並重組供應鏈以降低關稅帶來的成本增加。

透過按產品、藥物類別、患者人口統計特徵、疾病階段、最終用戶和分銷管道對阿茲海默症解決方案進行細分，解讀獲得的核心見解。

詳細的市場區隔分析清楚展現了阿茲海默症治療領域創新、投資和應用交會的領域。以產品類型檢驗市場發現，診斷方法（包括生物標記、基因檢測、CT、MRI、EEG 和 PET 等影像技術以及簡易精神狀態檢查 (MMSE) 等神經心理測試）與治療支柱（包括聯合治療、藥物治療和非藥物干預，例如認知刺激療法）同步發展。血液生物標記和腦脊髓液 (CSF) 檢測正逐漸成為增強早期檢測能力的輔助診斷方法。

了解美洲、歐洲、中東、非洲和亞太地區阿茲海默症護理和研究的區域差異和戰略機會。

要全面了解阿茲海默症的複雜現狀，需要從區域觀點。在美洲，完善的醫療基礎設施、廣泛的學術合作以及對生物標記研究的大量投入，正在加速先進診斷測試和治療試驗的推廣應用。該地區率先部署了基於血液的生物標記檢測組合，並利用廣泛的遠端醫療網路來擴大患者的就醫管道，尤其是在資源匱乏的農村地區。

分析主要企業的策略部署、創新組合以及為重新定義阿茲海默症診斷和治療市場而進行的合作努力。

阿茲海默症診斷和治療領域呈現出生命科學創新者、生物技術先驅和成熟製藥公司蓬勃發展的局面。主要企業已建立起整合生物標記發現、造影劑開發和新一代抗體工程的綜合研發平台。它們的策略發展通常包括與學術機構簽署合作研究協議、成立合資企業擴大生產規模以及透過許可協議拓展產品系列。

制定切實可行且具有前瞻性的建議，以支持產業領導者推動阿茲海默症的研究、診斷和治療策略。

產業領導者必須採取多管齊下的策略，以充分利用不斷發展的科學發現和不斷變化的政策環境。首先，將血液衍生生物標記與神經影像學和基因檢測結合，優先發展早期療育平台，可以加快臨床試驗的患者招募速度，並提高診斷的可靠性。建立跨學科聯盟，匯集分子生物學家、資料科學家和神經心理學家，將有助於開發下一代篩檢方案和數位診斷工具。

詳細介紹阿茲海默症市場研究中使用的嚴格調查方法，該方法結合了初步訪談、二手資料分析和專家檢驗。

本市場分析採用嚴謹的多階段調查方法。首先，進行了全面的二級研究，涵蓋同行評審文獻、臨床試驗註冊資訊、監管申報文件以及專有專利資料庫，以揭示診斷技術和治療方案的演變。提取了診斷準確率、治療反應率和臨床試驗受試者入組指標等關鍵績效指標（KPI），以建立比較基準。

本報告整合了關鍵發現、策略意義和未來前景，對阿茲海默症診斷和治療方法的現狀進行了全面評估。

本執行摘要闡述了阿茲海默症診斷和治療領域中技術創新、政策轉變和策略細分之間的動態互動。從先進生物標記檢測和人工智慧成像技術的出現，到應對關稅調整的策略舉措，該領域的特點是快速迭代和協作發展。透過產品類型、藥物類別、患者族群、疾病階段、最終用戶和分銷管道的詳細細分，揭示了建立滿足不同臨床和市場需求的解決方案的複雜性和潛在機會。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：阿茲海默症診斷與治療市場：按產品分類

  • 診斷
    • 生物標記
      • 血液衍生生物標記
      • 腦脊髓液（CSF）生物標記物
    • 基因檢測
    • 診斷影像
      • 電腦斷層掃描（CT）
      • 腦電圖（EEG）
      • 磁振造影（MRI）
      • 正子斷層掃描（PET）
    • 神經心理學測試
      • 用於確診失智症的八份調查問卷
      • 簡易精神狀態測試
      • 蒙特婁認知評估
      • 神經精神病學症狀評估調查問卷
  • 治療方法
    • 聯合治療
    • 藥物治療
    • 非藥物療法
      • 行為干預
      • 認知刺激療法

第9章：阿茲海默症診斷與治療市場：按藥物類別分類

  • 膽鹼酯酶抑制劑
    • 多奈哌齊
    • Galantamine
    • Rivastigmine
  • 單株抗體
    • 阿杜卡奴單抗
    • 多納內馬
    • 利卡那單抗
  • NMDA受體拮抗劑

第10章：阿茲海默症診斷與治療市場：按患者群體分類

  • 65-74歲
  • 75-84歲
  • 85歲或以上
  • 65歲以下

第11章：阿茲海默症診斷與治療市場：依疾病階段分類

  • 阿茲海默症早期
  • 阿茲海默症晚期
  • 中期阿茲海默症

第12章：阿茲海默症診斷與治療市場：按最終用戶分類

  • 學術和研究機構
  • 診斷中心
  • 居家照護設施
  • 醫院和診所

第13章：阿茲海默症診斷與治療市場：按分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第14章：阿茲海默症診斷與治療市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：阿茲海默症診斷與治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章：阿茲海默症診斷與治療市場：按國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國：阿茲海默症診斷與治療藥物市場

第18章 中國：阿茲海默症診斷與治療藥物市場

第19章 競爭情勢

  • 2024年市場集中度分析
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2024 年
  • 2024年產品系列分析
  • 基準分析，2024 年
  • Abbvie Inc.
  • AC Immune SA
  • Alector, Inc.
  • Alzheon, Inc.
  • Amylyx Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • Biogen Inc.
  • BioXcel Therapeutics Inc.
  • Bristol-Myers Squibb Company
  • Cognoptix Inc.
  • Corium Inc.
  • Danaher Corporation
  • Denali Therapeutics Inc.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GE Healthcare
  • Grifols, SA
  • H. Lundbeck A/S
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Luye Pharma Group Ltd.
  • Merck & Co. Inc.
  • Muna Therapeutics
  • Novartis AG
  • Quest Diagnostics Incorporated
  • Sanofi SA
  • Siemens Healthineers AG
  • Takeda Pharmaceutical Company Limited
  • TauRx Therapeutics Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Thermo Fisher Scientific Inc.
  • Voyager Therapeutics, Inc.
  • Zydus Lifesciences Limited
Product Code: MRR-742BD517AA98

The Alzheimer's Disease Diagnostics & Therapeutics Market was valued at USD 8.35 billion in 2024 and is projected to grow to USD 9.12 billion in 2025, with a CAGR of 9.50%, reaching USD 14.41 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 8.35 billion
Estimated Year [2025] USD 9.12 billion
Forecast Year [2030] USD 14.41 billion
CAGR (%) 9.50%

Unveiling the Critical Context, Scientific Imperatives, and Industry Drivers Shaping the Future of Alzheimer's Disease Diagnostics and Therapeutics

The global response to Alzheimer's disease has reached an inflection point. Advances in molecular biology, neuroimaging, and biomarker discovery are converging to redefine how the disease is diagnosed and treated. What was once considered an inevitable decline is now subject to rigorous scientific inquiry that is unlocking new diagnostic modalities and therapeutic approaches. With patients, caregivers, clinicians, and policymakers demanding earlier detection and more precise interventions, stakeholders across academia, industry, and regulatory bodies are mobilizing to meet this pressing need.

In recent years, diagnostic paradigms have shifted from purely clinical assessments to integrated models that leverage blood-based biomarkers, cerebrospinal fluid analyses, high-resolution magnetic resonance imaging, positron emission tomography, and sophisticated neuropsychological batteries such as the Montreal Cognitive Assessment and the Ascertain Dementia 8 instrument. At the same time, the therapeutic landscape is evolving beyond conventional drug monotherapies to embrace combination regimes, monoclonal antibodies targeting amyloid and tau, and non-pharmacological approaches like cognitive stimulation therapy and behavioral interventions.

This introduction sets the stage for an in-depth exploration of transformative shifts, tariff implications, segmentation insights, regional dynamics, and strategic recommendations. By synthesizing the latest data, expert perspectives, and methodological rigor, this report aims to equip decision-makers with the clarity and foresight needed to navigate the complex Alzheimer's ecosystem and to accelerate innovation for the millions of individuals and families affected worldwide.

Identifying the Transformative Shifts Redefining Alzheimer's Research, Diagnostic Innovation, and Therapeutic Strategies in a Rapidly Evolving Healthcare Ecosystem

The Alzheimer's disease arena is witnessing a profound transformation driven by breakthroughs in biomarker validation, next-generation imaging, and digital health integration. Early on, the field pivoted from relying solely on symptomatic assessments to embracing molecular diagnostics that detect pathogenic processes long before clinical onset. This shift has catalyzed the development of targeted monoclonal antibodies, disease-modifying small molecules, and combination strategies that aim to intervene at asymptomatic and prodromal stages.

Simultaneously, the integration of artificial intelligence and machine learning into imaging techniques such as MRI, CT, and PET scans is enabling unprecedented precision in lesion detection and progression monitoring. Genetic testing advancements are refining risk stratification frameworks, while neuropsychological testing innovations are enhancing cognitive profiling with tools like the Neuropsychiatric Inventory Questionnaire. On the therapeutic side, the blending of non-drug modalities-including cognitive stimulation and behavioral interventions-with pharmacological regimens is reshaping patient care models.

Healthcare systems are adapting to these innovations by expanding homecare settings, upgrading diagnostic center capabilities, and fostering cross-sector collaborations between hospitals, academic institutions, and technology partners. These dynamics are creating an ecosystem in which data interoperability, regulatory agility, and patient-centric design are increasingly recognized as critical enablers of successful Alzheimer's interventions. This section unpacks these transformative shifts, illustrating how interconnected advancements are redefining the research, development, and delivery of diagnostics and therapeutics in Alzheimer's disease.

Evaluating the Multifaceted Consequences of the 2025 United States Tariffs on Alzheimer's Disease Diagnostics, Therapeutics, and Global Supply Chain Dynamics

The introduction of new tariffs on diagnostic equipment, therapeutics manufacturing inputs, and research reagents by the United States in 2025 has rippled across the Alzheimer's disease landscape. These policy adjustments have influenced sourcing strategies for biomarkers, imaging agents, and monoclonal antibody components. Facilities that once relied on cost-effective imports are now evaluating domestic production capabilities and realigning supply chains to mitigate tariff-driven cost escalations.

On the diagnostics front, increased duties on specialized imaging hardware and cerebrospinal fluid assay kits have prompted diagnostic centers and academic research institutes to reassess capital expenditure and maintenance budgets. This in turn has accelerated the exploration of blood-based biomarker assays and decentralized testing models that reduce reliance on high-cost imports. Within therapeutics, the tariffs have impacted the raw materials essential for producing cholinesterase inhibitors, NMDA receptor antagonists, and monoclonal antibodies such as aducanumab and lecanemab.

The cumulative effect has been a strategic pivot toward regional manufacturing hubs and localized distribution channels. Online and retail pharmacies are adapting to ensure patient access despite cost pressures, while hospital pharmacies are forging partnerships with domestic suppliers. Regulatory bodies are also streamlining approval pathways to encourage local production. As a result, stakeholders are balancing the need to maintain affordability and accessibility with the imperative to invest in innovation. This section delves into the nuanced implications of the 2025 tariffs and how they are driving adaptive strategies across the Alzheimer's diagnostics and therapeutics ecosystem.

Deciphering Core Insights from Product, Drug Class, Patient Demographics, Disease Stages, End Users, and Distribution Channel Segmentations Driving Alzheimer's Solutions

An in-depth segmentation analysis provides a granular view of where innovation, investment, and adoption converge in Alzheimer's disease care. Examining the market by product type reveals that diagnostic modalities-comprising biomarkers, genetic tests, imaging techniques such as CT, MRI, EEG, and PET, and neuropsychological batteries like the Mini-Mental State Exam-are advancing alongside therapeutic pillars that include combination therapies, drug treatments, and non-drug interventions such as cognitive stimulation therapy. Blood-based biomarkers and cerebrospinal fluid assays are emerging as complementary diagnostic streams that enhance early detection capabilities.

When viewed through the lens of drug class, cholinesterase inhibitors such as donepezil, galantamine, and rivastigmine continue to serve as foundational therapies, while monoclonal antibodies including aducanumab, donanemab, and lecanemab are redefining disease-modifying treatment approaches. NMDA receptor antagonists also play a pivotal role in addressing symptomatic management. Patient demographic segmentation highlights the nuanced needs of those aged 65 to 74 years, 75 to 84 years, above 85 years, and the emerging considerations for individuals below 65 years who may present early-onset pathology.

Stage-based differentiation underscores the contrast between early-stage, middle-stage, and late-stage Alzheimer's, each demanding tailored intervention strategies and care delivery models. End users-spanning academic and research institutes, diagnostic centers, homecare settings, and hospitals and clinics-drive distinct adoption cycles, while distribution channels comprising hospital, online, and retail pharmacies shape accessibility and patient engagement. This comprehensive segmentation lens illuminates the multifaceted pathways through which diagnostics and therapeutics are researched, delivered, and integrated into patient care.

Uncovering Regional Variations and Strategic Opportunities across Americas, Europe Middle East and Africa, and Asia Pacific for Alzheimer's Care and Research

Regional perspectives are paramount to understanding the heterogeneous Alzheimer's disease landscape. In the Americas, robust healthcare infrastructure, extensive academic collaborations, and substantial investment in biomarker research have accelerated the adoption of advanced diagnostic assays and therapeutic trials. This region is pioneering blood-based biomarker panels and leveraging widespread telehealth networks to expand patient access, particularly in under-resourced rural communities.

Within Europe, Middle East, and Africa, regulatory convergence and cross-border research consortia are driving standardization of imaging protocols and genetic testing frameworks. Nations are investing in the integration of neuropsychological testing instruments, such as the Montreal Cognitive Assessment, into primary care pathways. Concurrently, localized production of monoclonal antibodies and small molecules is gaining traction, supported by favorable policy incentives and public-private partnerships.

In the Asia-Pacific region, rapid demographic aging, burgeoning homecare models, and digital health innovations are propelling demand for decentralized diagnostic tools and non-drug interventions. Behavioral interventions and cognitive stimulation programs are being adapted to local cultural contexts, while emerging biotech hubs are forging alliances with global pharmaceutical companies to accelerate clinical development. Each region's unique regulatory landscape, patient demographics, and healthcare delivery infrastructure create differentiated opportunities and challenges. This section explores these regional nuances, offering strategic guidance on how stakeholders can tailor their approaches to maximize impact and accessibility.

Analyzing Key Industry Players' Strategic Footprints, Innovation Portfolios, and Collaborative Efforts Redefining Alzheimer's Diagnostics and Therapeutics Markets

The Alzheimer's diagnostics and therapeutics sector is characterized by a dynamic mix of life science innovators, biotechnology pioneers, and established pharmaceutical firms. Leading companies have established comprehensive R&D platforms that integrate biomarker discovery, imaging agent development, and next-generation antibody engineering. Their strategic footprints often include collaborative research agreements with academic centers, joint ventures for manufacturing scale-up, and licensing arrangements to broaden their product portfolios.

In diagnostics, firms specializing in blood-based assays are forging partnerships with neuroimaging companies to develop multimodal screening solutions. Imaging technology providers are embedding artificial intelligence algorithms to enhance lesion detection and predictive analytics. On the therapeutics front, biotechnology companies focused on monoclonal antibodies are investing heavily in clinical pipeline expansion, while pharmaceutical incumbents are strengthening their small molecule and combination therapy offerings to maintain competitive positioning.

This landscape is further shaped by emerging players that are commercializing digital cognitive assessment platforms and novel non-drug interventions. Their agility in navigating regulatory surfaces and digital health approval pathways positions them as potential disruptors. Collectively, these enterprises are influencing pricing models, market access strategies, and global distribution frameworks. This section delves into the strategic initiatives, innovation trajectories, and collaborative networks of key companies, illuminating how they are driving the evolution of Alzheimer's disease diagnostics and therapeutics.

Formulating Practical and Forward-Looking Recommendations to Empower Industry Leaders in Advancing Alzheimer's Disease Research, Diagnostics, and Treatment Strategies

Industry leaders must adopt a multifaceted strategy to harness evolving scientific discoveries and shifting policy landscapes. First, prioritizing early-stage intervention platforms by integrating blood-based biomarkers with neuroimaging and genetic testing can accelerate clinical trial enrollment and improve diagnostic confidence. Establishing cross-disciplinary consortia that unify molecular biologists, data scientists, and neuropsychologists will catalyze the development of next-generation screening panels and digital diagnostic tools.

Second, diversifying therapeutic portfolios through strategic acquisitions or licensing deals can enhance access to novel monoclonal antibodies and non-drug interventions. By forging partnerships with academic research institutes and biotech startups, companies can leverage precompetitive data, share development risks, and expedite regulatory submissions. Simultaneously, investing in regional manufacturing capabilities and supply chain resilience will mitigate tariff impacts and ensure consistent product availability across diverse markets.

Third, adopting a patient-centric approach that tailors care pathways to demographic and disease-stage nuances will differentiate value propositions. This includes customizing treatment regimens for patients aged 65 to 74 years versus those above 85 years, and integrating cognitive stimulation therapy within homecare settings. Finally, embedding real-world evidence collection within diagnostic and therapeutic roll-outs will strengthen payer negotiations and support reimbursement frameworks. By executing these recommendations, industry stakeholders can align innovation with market imperatives, delivering sustainable growth and improved patient outcomes.

Detailing the Rigorous Research Methodology Integrating Primary Interviews, Secondary Data Analysis, and Expert Validation for Alzheimer's Market Study

This market analysis integrates a rigorous multi-stage research methodology. Initially, a comprehensive secondary review was conducted, encompassing peer-reviewed literature, clinical trial registries, regulatory filings, and proprietary patent databases to map the evolution of diagnostic technologies and therapeutic pipelines. Key performance indicators, such as diagnostic accuracy, treatment response rates, and clinical trial enrollment metrics, were extracted to establish comparative benchmarks.

Subsequently, primary research involved in-depth interviews with leading neurologists, research scientists, regulatory experts, and supply chain executives. These qualitative insights provided context on adoption barriers, reimbursement challenges, and strategic collaboration models. Concurrently, quantitative surveys were administered to diagnostic centers, hospitals, pharmacies, and homecare providers to capture deployment trends across different end-user segments and distribution channels.

Data triangulation ensured the validation of findings by cross-referencing primary inputs with secondary data points and incorporating feedback loops from industry advisory panels. This iterative validation process underpinned the development of segmentation frameworks, tariff impact assessments, and regional insights. Finally, an internal expert review panel, comprising neuropsychologists, pharmacologists, and health economists, scrutinized the analysis for methodological robustness and factual accuracy. This structured approach guarantees that the conclusions and recommendations presented are grounded in comprehensive evidence and reflective of the current Alzheimer's disease diagnostics and therapeutics ecosystem.

Synthesizing Critical Findings, Strategic Implications, and Future Outlook to Conclude the Alzheimer's Disease Diagnostics and Therapeutics Landscape Assessment

This executive summary has mapped the dynamic interplay of technological innovation, policy shifts, and strategic segmentation within Alzheimer's disease diagnostics and therapeutics. From the emergence of advanced biomarker assays and AI-enhanced imaging modalities to the strategic responses to tariff adjustments, the landscape is characterized by rapid iteration and collaborative advancement. Detailed segmentation across product types, drug classes, patient demographics, disease stages, end users, and distribution channels has revealed the complexity and opportunity inherent in tailoring solutions to diverse clinical and market needs.

Regional insights have underscored the importance of localized strategies, whether it be the Americas' emphasis on telehealth and rural access, the EMEA region's drive for regulatory harmonization, or the Asia-Pacific focus on decentralization and cultural adaptation of non-drug therapies. The strategic footprints of leading companies, combined with the actionable recommendations outlined, form a roadmap for stakeholders seeking to navigate competitive pressures, regulatory demands, and unmet clinical needs.

Looking ahead, the convergence of precision diagnostics, personalized therapeutics, and data-driven decision support systems is poised to accelerate disease modification efforts and improve patient outcomes. This conclusion synthesizes the critical findings and underscores the imperative for continued collaboration, innovation, and patient-centric focus as the Alzheimer's disease ecosystem evolves.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2024
  • 3.5. FPNV Positioning Matrix, 2024
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Alzheimer's Disease Diagnostics & Therapeutics Market, by Product

  • 8.1. Diagnostics
    • 8.1.1. Biomarkers
      • 8.1.1.1. Blood-Based Biomarkers
      • 8.1.1.2. Cerebrospinal Fluid (CSF) Biomarkers
    • 8.1.2. Genetic Testing
    • 8.1.3. Imaging Techniques
      • 8.1.3.1. Computed Tomography (CT) Scans
      • 8.1.3.2. Electroencephalogram (EEG)
      • 8.1.3.3. Magnetic Resonance Imaging (MRI)
      • 8.1.3.4. Positron Emission Tomography (PET)
    • 8.1.4. Neuropsychological Testing
      • 8.1.4.1. Ascertain Dementia 8
      • 8.1.4.2. Mini-Mental State Exam
      • 8.1.4.3. Montreal Cognitive Assessment
      • 8.1.4.4. Neuropsychiatric Inventory Questionnaire
  • 8.2. Therapeutics
    • 8.2.1. Combination Therapies
    • 8.2.2. Drug Therapies
    • 8.2.3. Non-Drug Therapies
      • 8.2.3.1. Behavioral Interventions
      • 8.2.3.2. Cognitive Stimulation Therapy

9. Alzheimer's Disease Diagnostics & Therapeutics Market, by Drug Class

  • 9.1. Cholinesterase Inhibitors
    • 9.1.1. Donepezil
    • 9.1.2. Galantamine
    • 9.1.3. Rivastigmine
  • 9.2. Monoclonal Antibodies
    • 9.2.1. Aducanumab
    • 9.2.2. Donanemab
    • 9.2.3. Lecanemab
  • 9.3. NMDA Receptor Antagonists

10. Alzheimer's Disease Diagnostics & Therapeutics Market, by Patient Demographics

  • 10.1. 65-74 Years
  • 10.2. 75-84 Years
  • 10.3. Above 85 Years
  • 10.4. Below 65 Years

11. Alzheimer's Disease Diagnostics & Therapeutics Market, by Disease Stage

  • 11.1. Early-Stage Alzheimer's
  • 11.2. Late-Stage Alzheimer's
  • 11.3. Middle-Stage Alzheimer's

12. Alzheimer's Disease Diagnostics & Therapeutics Market, by End User

  • 12.1. Academic & Research Institutes
  • 12.2. Diagnostic Centers
  • 12.3. Homecare Settings
  • 12.4. Hospitals & Clinics

13. Alzheimer's Disease Diagnostics & Therapeutics Market, by Distribution Channel

  • 13.1. Hospital Pharmacies
  • 13.2. Online Pharmacies
  • 13.3. Retail Pharmacies

14. Alzheimer's Disease Diagnostics & Therapeutics Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Alzheimer's Disease Diagnostics & Therapeutics Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Alzheimer's Disease Diagnostics & Therapeutics Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Alzheimer's Disease Diagnostics & Therapeutics Market

18. China Alzheimer's Disease Diagnostics & Therapeutics Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2024
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2024
  • 19.3. Product Portfolio Analysis, 2024
  • 19.4. Benchmarking Analysis, 2024
  • 19.5. Abbvie Inc.
  • 19.6. AC Immune SA
  • 19.7. Alector, Inc.
  • 19.8. Alzheon, Inc.
  • 19.9. Amylyx Pharmaceuticals, Inc.
  • 19.10. AstraZeneca PLC
  • 19.11. Aurobindo Pharma Limited
  • 19.12. Biogen Inc.
  • 19.13. BioXcel Therapeutics Inc.
  • 19.14. Bristol-Myers Squibb Company
  • 19.15. Cognoptix Inc.
  • 19.16. Corium Inc.
  • 19.17. Danaher Corporation
  • 19.18. Denali Therapeutics Inc.
  • 19.19. Eisai Co., Ltd.
  • 19.20. Eli Lilly and Company
  • 19.21. F. Hoffmann-La Roche AG
  • 19.22. GE Healthcare
  • 19.23. Grifols, S.A.
  • 19.24. H. Lundbeck A/S
  • 19.25. Johnson & Johnson Services, Inc.
  • 19.26. Lupin Limited
  • 19.27. Luye Pharma Group Ltd.
  • 19.28. Merck & Co. Inc.
  • 19.29. Muna Therapeutics
  • 19.30. Novartis AG
  • 19.31. Quest Diagnostics Incorporated
  • 19.32. Sanofi S.A.
  • 19.33. Siemens Healthineers AG
  • 19.34. Takeda Pharmaceutical Company Limited
  • 19.35. TauRx Therapeutics Ltd.
  • 19.36. Teva Pharmaceutical Industries Ltd.
  • 19.37. Thermo Fisher Scientific Inc.
  • 19.38. Voyager Therapeutics, Inc.
  • 19.39. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 2. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 3. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 4. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 14. CHINA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 2. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 3. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 7. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BLOOD-BASED BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BLOOD-BASED BIOMARKERS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BLOOD-BASED BIOMARKERS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CEREBROSPINAL FLUID (CSF) BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CEREBROSPINAL FLUID (CSF) BIOMARKERS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CEREBROSPINAL FLUID (CSF) BIOMARKERS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNIQUES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNIQUES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNIQUES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COMPUTED TOMOGRAPHY (CT) SCANS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COMPUTED TOMOGRAPHY (CT) SCANS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COMPUTED TOMOGRAPHY (CT) SCANS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ELECTROENCEPHALOGRAM (EEG), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ELECTROENCEPHALOGRAM (EEG), BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ELECTROENCEPHALOGRAM (EEG), BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING (MRI), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING (MRI), BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING (MRI), BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY (PET), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY (PET), BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY (PET), BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NEUROPSYCHOLOGICAL TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NEUROPSYCHOLOGICAL TESTING, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NEUROPSYCHOLOGICAL TESTING, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NEUROPSYCHOLOGICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ASCERTAIN DEMENTIA 8, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ASCERTAIN DEMENTIA 8, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ASCERTAIN DEMENTIA 8, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MINI-MENTAL STATE EXAM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MINI-MENTAL STATE EXAM, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MINI-MENTAL STATE EXAM, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MONTREAL COGNITIVE ASSESSMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MONTREAL COGNITIVE ASSESSMENT, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MONTREAL COGNITIVE ASSESSMENT, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NEUROPSYCHIATRIC INVENTORY QUESTIONNAIRE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NEUROPSYCHIATRIC INVENTORY QUESTIONNAIRE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NEUROPSYCHIATRIC INVENTORY QUESTIONNAIRE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 55. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 56. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 57. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 58. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 60. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG THERAPIES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 61. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG THERAPIES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 62. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-DRUG THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 63. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-DRUG THERAPIES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 64. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-DRUG THERAPIES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 65. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-DRUG THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 66. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BEHAVIORAL INTERVENTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 67. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BEHAVIORAL INTERVENTIONS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 68. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BEHAVIORAL INTERVENTIONS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 69. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COGNITIVE STIMULATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 70. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COGNITIVE STIMULATION THERAPY, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 71. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COGNITIVE STIMULATION THERAPY, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 72. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 73. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 74. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 75. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 76. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 77. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DONEPEZIL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 78. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DONEPEZIL, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 79. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DONEPEZIL, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 80. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GALANTAMINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 81. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GALANTAMINE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 82. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GALANTAMINE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 83. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RIVASTIGMINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 84. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RIVASTIGMINE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 85. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RIVASTIGMINE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 86. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 87. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 88. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 89. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 90. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ADUCANUMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 91. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ADUCANUMAB, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 92. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ADUCANUMAB, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 93. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DONANEMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 94. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DONANEMAB, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 95. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DONANEMAB, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 96. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY LECANEMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 97. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY LECANEMAB, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 98. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY LECANEMAB, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 99. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 100. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 101. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 102. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 103. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY 65-74 YEARS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 104. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY 65-74 YEARS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 105. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY 65-74 YEARS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 106. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY 75-84 YEARS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 107. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY 75-84 YEARS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 108. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY 75-84 YEARS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 109. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ABOVE 85 YEARS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 110. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ABOVE 85 YEARS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 111. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ABOVE 85 YEARS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 112. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BELOW 65 YEARS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 113. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BELOW 65 YEARS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 114. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BELOW 65 YEARS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 115. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 116. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EARLY-STAGE ALZHEIMER'S, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 117. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EARLY-STAGE ALZHEIMER'S, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 118. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EARLY-STAGE ALZHEIMER'S, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 119. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY LATE-STAGE ALZHEIMER'S, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 120. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY LATE-STAGE ALZHEIMER'S, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 121. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY LATE-STAGE ALZHEIMER'S, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 122. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MIDDLE-STAGE ALZHEIMER'S, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 123. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MIDDLE-STAGE ALZHEIMER'S, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 124. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MIDDLE-STAGE ALZHEIMER'S, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 125. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 126. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 127. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 128. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 129. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 130. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 131. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 132. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 133. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 134. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 135. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 136. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 137. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 138. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 140. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 141. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 142. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 143. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 144. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 145. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 146. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 147. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 148. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 149. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2030 (USD MILLION)
  • TABLE 150. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 151. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 152. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 153. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 154. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NEUROPSYCHOLOGICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 155. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 156. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-DRUG THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 157. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 158. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 159. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 160. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 161. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 162. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 163. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 164. NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 165. NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 166. NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 167. NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 168. NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 169. NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NEUROPSYCHOLOGICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 170. NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 171. NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-DRUG THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 172. NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 173. NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 174. NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 175. NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 176. NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 177. NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 178. NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 179. LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 180. LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 181. LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 182. LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 183. LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 184. LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NEUROPSYCHOLOGICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 185. LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 186. LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-DRUG THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 187. LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 188. LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 189. LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 190. LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 191. LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 192. LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 193. LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2030 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NEUROPSYCHOLOGICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-DRUG THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 209. EUROPE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 210. EUROPE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 211. EUROPE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 212. EUROPE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 213. EUROPE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 214. EUROPE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NEUROPSYCHOLOGICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 215. EUROPE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 216. EUROPE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-DRUG THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 217. EUROPE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 218. EUROPE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 219. EUROPE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 220. EUROPE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 221. EUROPE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 222. EUROPE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 223. EUROPE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 224. MIDDLE EAST ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 225. MIDDLE EAST ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 226. MIDDLE EAST ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 227. MIDDLE EAST ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 228. MIDDLE EAST ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 229. MIDDLE EAST ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NEUROPSYCHOLOGICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 230. MIDDLE EAST ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 231. MIDDLE EAST ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-DRUG THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 232. MIDDLE EAST ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 233. MIDDLE EAST ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 234. MIDDLE EAST ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 235. MIDDLE EAST ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 236. MIDDLE EAST ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 237. MIDDLE EAST ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 238. MIDDLE EAST ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 239. AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 240. AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 241. AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 242. AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 243. AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 244. AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NEUROPSYCHOLOGICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 245. AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 246. AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-DRUG THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 247. AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 248. AFRICA AL